medical biz

University of Houston introduces institute to bring business solutions to health care industry

UH's C. T. Bauer College of Business will house the newly launched Healthcare Business Institute. Photo via Getty Images

The University of Houston announced this month that it has now launched its new Healthcare Business Institute, which will work with medical and business leaders as well as students to find solutions to pressing issues in the health care industry, such as high costs, access to care and new innovative technologies.

The institute will be part of the university's C. T. Bauer College of Business and led by Ravi Aron, research director and professor of health care strategy and technology in the Bauer College Department of Decision & Information Sciences, and Dr. Edward Kroger, the administrative director of the center.

“Providers are facing increasingly limited reimbursement from the U.S. government, insurers and employers. The industry is, therefore, struggling with finding new ways to increase value by improving quality and decreasing cost,” Aron says in a statement. “This is complicated by the fact that the industry is the most heavily regulated in the country. While policy, regulations and the government all have roles to play, efficient care delivery also requires businesses–small, medium, large and startups-to play a significant role in delivering effective and efficient care.”

The institute plans to bring together stakeholders from device makers and pharmaceutical companies to angel investors and educators to address many of these issues. Faculty and partners will release impactful research on topics such as hospital operations, new health care technologies, AI and machine learning in hospital contexts, emerging financial models in health care and a number of other topics.

Research will be shared in a new practitioner-facing Knowledge Portal that will feature a journal, editorials, and other media components like blogs, videos and audio.

The HBI will also have an educational component, with formal degree-based and shorter non-degree tracts, as well as a masters program related to health care leadership. Multiple executive education programs are also in the works.

“This unique combination of researchers, educationists and students will also benefit by connecting to perhaps the world’s most diversified health care ecosystem,” Aron says in the statement.

And Houston is the right place to house such an institute, says Bauer College Dean and Cullen Distinguished Chair Professor Paul A. Pavlou.

“Technology, data, and AI are enabling unprecedented advances in medicine, and Houston’s impressive health care network presents an exciting opportunity for a Healthcare Business Institute,” Pavlou says in the release. “Not only is Houston home to the Texas Medical Center, UH is the only university in Houston that includes a large number of health care researchers at the Bauer College of Business, a world-ranked health law program at the UH Law Center, a computer science department with many distinguished research faculty, and a new College of Medicine."

“The opportunity for meaningful collaboration among health care researchers, industry leaders, and students through HBI will be a tremendous asset for Houston with the potential for local, national and global impact,” he continues.

Earlier this summer, UH announced plans to open a 70,000-square-foot innovation hub next to the M.D. Anderson Library on UH's main campus in 2025. It's slated to house a makerspace, the Cyvia and Melvyn Wolff Center for Entrepreneurship, the Energy Transition Institute, innovation programs, and Presidential Frontier Faculty labs and offices.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted